TargaGenix Inc.

company

About

TargaGenix Inc. is developing a novel nanoemulsion formulation of a novel chemotherapy for the treatment of cancer

  • 1 - 10

Details

Last Funding Type
Seed
Last Funding Money Raised
$100K
Industries
Biotechnology,Chemical,Health Care
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

was founded in 2013 to develop novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$100K
TargaGenix Inc. has raised a total of $100K in funding over 2 rounds. Their latest funding was raised on Sep 16, 2018 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 16, 2018 Seed $100K 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
TargaGenix Inc. is funded by 1 investors. AJI Capital are the most recent investors.
Investor Name Lead Investor Funding Round
AJI Capital Seed